• Deutsch
  • English
  • Français
  • Русский
  • Română
  • Español
  • Български

TauroLock™

Das antimikrobielle Katheter-Locksystem

TauroLock™ is more cost-efficient than 4 % citrate.

Comparison of our TauroLock™ 2+1 protocol (TauroLock™-Hep500 twice weekly and TauroLock™-U25.000 once weekly) versus 4 % citrate.

 

Methods:

The study was performed as a prospective, multicenter, randomized, controlled trial in hemodialysis patients using newly inserted tunneled central venous catheters (in total 15,690 catheter days).

 

Results:

1. Catheter-related infections (CRBSI):

Significantly lower rate with TauroLock™ 2+1:

0.67 vs. 2.7/1000 catheter days in 4 % citrate group (p=0.003).

2. Catheter dysfunction (flow ≤ 200 ml/min):

Significantly lower rate with TauroLock™ 2+1:

18.7 vs. 44.3/1000 catheter days in 4 % citrate group (p=0.001).

Significantly more frequent use of alteplase rescue in the citrate group (9.8 vs. 3.8/1000 catheter days, p=0.001).

3. Cost savings:

Significant cost savings with TauroLock™ 2+1:

43 % of overall expenses per patient and year.

 

Conclusion:

TauroLock™ 2+1 was significantly superior regarding all catheter-related aspects (infection prevention and function) and even cut expenses to half of those with 4 % citrate.